Filing Analysis
Kyntra Bio, Inc. filed an 8-K to announce its quarterly financial results for the period ending June 30, 2026.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing is a standard announcement of financial results via press release (Exhibit 99.1).
Kyntra Bio reported the results of its 2026 annual meeting of stockholders held on June 12, 2026. Stockholders elected a Class III director, approved executive compensation on an advisory basis, and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor.
📋 Key Facts
- Michael Kauffman, M.D., Ph.D. was elected as a Class III director with 96.04% of the voting shares (1,239,169 shares for).
- Executive compensation for named executive officers was approved on an advisory basis (1,242,005 shares for, 23,606 against).
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026 (2,712,825 shares for).
- The meeting took place on June 12, 2026.
Kyntra Bio received a final payment of $4.0 million from AstraZeneca, representing the final indemnity holdback from the sale of its China operations. This payment completes all financial obligations owed to the company under the Share Purchase Agreement dated February 20, 2025.
📋 Key Facts
- Received $4.0 million from AstraZeneca Treasury Limited on June 2, 2026.
- Payment represents the final holdback for indemnity claims from the sale of China operations.
- The original transaction closed on August 29, 2025, for total consideration of approximately $220 million ($85M enterprise value + $135M net cash).
- Previous payments included $210 million at closing and a $6.4 million adjustment payment in November 2025.
Kyntra Bio, Inc. announced its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the 8-K filing.
📋 Key Facts
- The filing reports financial results for the fiscal quarter ended March 31, 2026.
- The information was disclosed under Item 2.02 (Results of Operations and Financial Condition).
- A press release dated May 11, 2026, was included as Exhibit 99.1.
- The report was signed by David DeLucia, Senior Vice President and Chief Financial Officer.
Kyntra Bio, Inc. received a deficiency notice from Nasdaq on April 2, 2026, for failing to meet the $50 million total assets and revenue requirement for continued listing on the Nasdaq Global Select Market. The company also confirmed it does not meet alternative listing standards regarding shareholders' equity or market value of listed securities.
🚩 Red Flags
- Failure to meet multiple alternative listing standards (equity and market value) simultaneously.
- Significant revenue impact from assets held for sale/discontinued operations in consecutive years (2024-2025).
- Potential for delisting if a compliance plan is not accepted or executed.
📋 Key Facts
- Received Nasdaq notification on April 2, 2026, regarding non-compliance with Listing Rule 5450(b)(3)(A).
- Non-compliance resulted from FibroGen International revenue being classified as held for sale/discontinued operations in 2024 and 2025.
- The company currently fails alternative requirements for shareholders' equity and market value of listed securities.
- Kyntra Bio has 45 days (until May 18, 2026) to submit a compliance plan to Nasdaq.
- If the plan is accepted, an extension of up to 180 days (until September 29, 2026) may be granted.
- The company is considering a transfer to the Nasdaq Capital Market as a potential remedy.
Kyntra Bio, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The results were disclosed via a press release furnished as Exhibit 99.1 to the filing.
📋 Key Facts
- Financial results reported for the quarter and year ended December 31, 2025
- Filing date and report date of March 16, 2026
- Information furnished under Item 2.02 (Results of Operations and Financial Condition)
- Signed by David DeLucia, Senior Vice President and Chief Financial Officer
FibroGen, Inc. has announced a formal name change to Kyntra Bio, Inc., effective January 7, 2026. The company's common stock will transition from the ticker symbol 'FGEN' to 'KYNB' on the Nasdaq Global Select Market starting January 8, 2026.
📋 Key Facts
- Company name changed from FibroGen, Inc. to Kyntra Bio, Inc.
- Effective date of name change: January 7, 2026, at 4:30 p.m. ET
- New ticker symbol: KYNB (formerly FGEN)
- CUSIP number remains unchanged (31572Q881)
- Trading under the new symbol begins January 8, 2026, at market open
FibroGen, Inc. filed an 8-K to announce the release of its financial results for the quarter ended September 30, 2025.
📋 Key Facts
- Report date: November 10, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
FibroGen, Inc. has received a $6.4 million payment from AstraZeneca, representing the release of a holdback related to the sale of its China operations. This follows the $220 million divestiture of its China business completed in August 2025.
📋 Key Facts
- Received $6.4 million from AstraZeneca Treasury Limited on November 6, 2025.
- The payment consists of a $6.0 million holdback release (final net cash adjustments) and an additional $0.4 million following final adjustments.
- The original transaction was the sale of China operations via FibroGen International (Hong Kong) Ltd. to AstraZeneca, closed on August 29, 2025.
- Total consideration for the China operations was approximately $220 million ($85M enterprise value + $135M net cash in China).
- A remaining $4.0 million holdback exists to satisfy indemnity claims, scheduled for release nine months after closing.
FibroGen, Inc. has completed the sale of its subsidiary, FibroGen International (Hong Kong) Ltd., to AstraZeneca Treasury Limited for approximately $220 million. The transaction involves the divestiture of all issued and outstanding equity interests in the Hong Kong entity.
🚩 Red Flags
- Significant divestiture of a subsidiary may indicate a strategic shift or a need for immediate liquidity to fund core operations/R&D.
📋 Key Facts
- Transaction closed on August 29, 2025.
- The sale price was approximately $220 million.
- Buyer is AstraZeneca Treasury Limited.
- Asset sold: All issued and outstanding equity interests of FibroGen International (Hong Kong) Ltd.
- Unaudited pro forma financial information as of June 30, 2025, and for the year ended December 31, 2024, was provided in Exhibit 99.1.
FibroGen, Inc. has completed the sale of its Chinese subsidiary, FibroGen International (Hong Kong) Ltd., to AstraZeneca for approximately $220 million in total consideration. The transaction includes $85 million in enterprise value and $135 million in net cash held in China.
🚩 Red Flags
- Significant divestiture of a major asset (roxadustat assets in China) which may impact long-term revenue streams.
- Complexity of cash repatriation/holdbacks ($10M total holdback).
📋 Key Facts
- Total consideration: ~$220 million ($85M enterprise value + $135M net cash in China).
- Buyer: AstraZeneca Treasury Limited.
- Assets sold: All equity interests of FibroGen International (Hong Kong) Ltd., including roxadustat assets in China.
- Holdbacks: $6.0 million for net cash adjustments and $4.0 million for indemnity claims.
- Debt repayment: Company repaid an $81 million term loan facility to Morgan Stanley Tactical Value funds at closing.
FibroGen, Inc. announced that it received regulatory approval from the China State Administration for Market Regulation for the sale of its Chinese subsidiary (FibroGen International (Hong Kong) Ltd.) to AstraZeneca. The transaction includes all roxadustat assets in China and is expected to close in Q3 2025.
🚩 Red Flags
- Asset disposition involves the divestiture of all China-based assets for a key product (roxadustat) in that specific territory.
📋 Key Facts
- Regulatory approval received from China State Administration for Market Regulation for the sale of FibroGen China to AstraZeneca Treasury Limited.
- The sale includes all issued and outstanding equity interests of FibroGen International (Hong Kong) Ltd., encompassing roxadustat assets in China.
- Transaction is expected to close in the third quarter of 2025, subject to customary closing conditions.
- FibroGen will retain rights to roxadustat in the US, Canada, Mexico, and markets not held by AstraZeneca or licensed to Astellas Pharma Inc.
FibroGen entered into a Fourth Amendment to its existing financing agreement with lenders managed by Morgan Stanley Tactical Value. The amendment primarily reduces the company's minimum qualified cash balance requirement from $18.75 million to $15 million.
🚩 Red Flags
- Reduction in minimum cash requirements often indicates a need for greater liquidity flexibility or potential difficulty meeting previous higher cash thresholds.
📋 Key Facts
- Date of event: August 12, 2025
- Amendment type: Fourth Amendment to Financing Agreement dated April 29, 2023
- Lenders: Investment funds managed by Morgan Stanley Tactical Value
- Administrative Agent: Wilmington Trust National Association
- Cash requirement change: Minimum qualified cash balance reduced from $18.75 million to $15 million
FibroGen, Inc. filed an 8-K to announce the release of its financial results for the quarter ended June 30, 2025.
📋 Key Facts
- Report date: August 11, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) containing the financial results.
- Information under Item 2.02 is furnished rather than filed for purposes of Section 18 liability.
FibroGen, Inc. entered into a Third Amendment to its existing financing agreement with lenders managed by Morgan Stanley Tactical Value on July 14, 2025. The amendment primarily modifies liquidity requirements by reducing the minimum qualified cash balance requirement.
🚩 Red Flags
- Reduction in required cash balance may indicate tightening liquidity constraints or a need for greater operational flexibility due to cash burn.
📋 Key Facts
- Date of amendment: July 14, 2025
- Lenders: Investment funds managed by Morgan Stanley Tactical Value
- Administrative Agent: Wilmington Trust National Association
- Modification: Minimum qualified cash balance reduced from $22.5 million to $18.75 million.
FibroGen has entered into a Termination, Asset Transfer and License Agreement with HiFiBiO Inc., effectively ending their previous exclusive license agreement. In exchange, FibroGen is licensing its anti-CCR8 and anti-Gal-9 intellectual property to HiFiBiO in return for potential royalty streams.
🚩 Red Flags
- Termination of a previous material license agreement suggests a shift in strategic direction or inability to advance the asset independently.
- Revenue from this deal is contingent upon third-party sublicensing and successful commercialization by HiFiBiO, providing no immediate cash infusion.
📋 Key Facts
- Agreement date: June 12, 2025
- Termination of the Exclusive License and Option Agreement originally dated June 16, 2021 (amended Feb 14, 2024).
- FibroGen licenses anti-CCR8 and anti-Gal-9 IP to HiFiBiO.
- FibroGen to receive mid single-digit to low double-digit share of HiFiBiO’s license revenues if sublicensed.
- FibroGen to receive low double-digit share of HiFiBiO’s commercial royalties upon sublicensing.
- Potential for single-digit royalties based on worldwide net sales if HiFiBiO commercializes the assets.
FibroGen, Inc. is implementing a 1-for-25 reverse stock split effective June 16, 2025, to regain compliance with Nasdaq's minimum bid price requirement. The move follows a temporary exception granted by the Nasdaq Hearings Panel contingent on stockholder approval.
🚩 Red Flags
- Reverse stock split (typically a sign of extreme downward pressure on share price).
- Delisting risk/Nasdaq non-compliance history (previously received notice of non-compliance on March 12, 2025).
- Requirement to implement the split to avoid delisting from the Nasdaq Global Select Market.
📋 Key Facts
- A 1-for-25 reverse stock split will take effect at 5:00 p.m. ET on June 16, 2025.
- The purpose is to increase the minimum bid price to comply with Nasdaq Listing Rule 5450(a)(1).
- Stockholders approved the split during the Annual Meeting held on June 4, 2025.
- Trading will resume on a post-split basis at market open on June 17, 2025, under symbol 'FGEN'.
- Fractional shares will be paid out in cash based on the closing price on the effective date.
FibroGen, Inc. held its 2025 annual meeting of stockholders where shareholders approved a reverse stock split in the range of 1-for-10 to 1-for-25 to maintain Nasdaq compliance. The filing also reports director changes and an amendment to a financing agreement.
🚩 Red Flags
- Reverse stock split approved (indicates potential delisting risk/low share price)
- Nasdaq compliance issue requiring structural capital changes
- Reduction in minimum cash balance requirement in financing agreement may indicate liquidity management needs
📋 Key Facts
- Stockholders approved a reverse stock split (range: 1-for-10 to 1-for-25) to comply with Nasdaq listing requirements.
- Jeffrey L. Edwards was elected as Class II director until the 2028 annual meeting.
- Michael Kauffman, M.D., Ph.D., was appointed as a Class III director and joined the Audit and Compensation Committees.
- Aoife Brennan resigned from the Board effective June 4, 2025; no disagreement with management reported.
- The Company entered into a Second Amendment to its financing agreement with Morgan Stanley Tactical Value funds, reducing the minimum qualified cash balance requirement from $27 million to $22.5 million.
- PricewaterhouseCoopers LLP was ratified as the independent auditor for 2025.
FibroGen, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: May 12, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes a press release as Exhibit 99.1 regarding financial results.
FibroGen, Inc. amended and restated its bylaws to lower the quorum requirements for stockholder meetings and class votes.
🚩 Red Flags
- Lowering quorum requirements can sometimes be used by management to facilitate corporate actions with lower shareholder participation, though it is a common administrative adjustment.
📋 Key Facts
- Effective April 2, 2025, the Company amended and restated its Bylaws.
- Quorum requirement for all meetings of stockholders changed from a majority of outstanding shares to one-third (1/3) of outstanding shares entitled to vote.
- Quorum requirement for separate class or series votes changed from a majority of voting power present to one-third (1/3) of the voting power present.
FibroGen, Inc. announced the peer-reviewed publication of Phase 1 clinical trial results for FOR46 (FG-3246) in the Journal of Clinical Oncology. The study focused on an antibody-drug conjugate targeting CD46 for patients with metastatic castration-resistant prostate cancer.
📋 Key Facts
- Publication title: 'A Phase 1, First-in-Human Study of FOR46 (FG-3246)... in Patients with Metastatic Castration Resistant Prostate Cancer'.
- Journal: Journal of Clinical Oncology.
- Drug Profile: FOR46 (now FG-3246), an anti-CD46 antibody drug conjugate with a monomethyl auristatin E payload.
- Study Sponsor: Fortis Therapeutics.
- Report Date: March 28, 2025.
FibroGen, Inc. entered into two amendments to existing agreements with Fortis Therapeutics, Inc. regarding an Evaluation Agreement and an Option Agreement/Plan of Merger. The primary change is the extension of the option exercise deadline to December 31, 2027.
🚩 Red Flags
- Extension of deadlines in merger/option agreements can sometimes indicate a delay in achieving clinical or commercial milestones required for an exit or transaction.
📋 Key Facts
- Entered into Amendment No. 1 to the First Amended and Restated Evaluation Agreement on March 28, 2025.
- Entered into Amendment No. 1 to the First Amended and Restated Option Agreement and Plan of Merger on March 28, 2025.
- The amendments modify the option exercise deadline for both agreements to December 31, 2027.
FibroGen, Inc. received notice from Nasdaq that it failed to regain compliance with the minimum bid price rule ($1.00) by the March 11, 2025 deadline. While a delisting is scheduled for March 21, 2025, the company has filed an appeal which has stayed the delisting pending a hearing.
🚩 Red Flags
- Delisting notice from Nasdaq Global Select Market
- Failure to maintain minimum bid price of $1.00 for 30 consecutive business days
- Potential necessity of a reverse stock split to cure deficiency
- Risk of permanent delisting if the appeal is unsuccessful or compliance cannot be met within the extension period
📋 Key Facts
- Nasdaq notified the company on March 12, 2025, that it failed to meet the minimum bid price requirement of $1.00 per share.
- Delisting was scheduled for the opening of business on March 21, 2025, unless an appeal was requested.
- The company filed an appeal on March 14, 2025, which has successfully stayed the delisting process.
- The company is seeking a hearing before the Nasdaq Hearings Panel to obtain an additional 180-day compliance period.
- Management explicitly mentioned that a reverse stock split may be necessary to regain compliance.
FibroGen, Inc. entered into an 'at-the-market' (ATM) equity offering sales agreement with BofA Securities, Inc. to facilitate the sale of common stock for up to $30.0 million in aggregate proceeds.
🚩 Red Flags
- Potential for significant shareholder dilution through the issuance of new common stock.
- ATM offerings are often used by micro-cap/small-cap biotech companies to fund ongoing operations (burn rate management).
📋 Key Facts
- Entered into ATM Equity Offering Sales Agreement with BofA Securities, Inc. on February 24, 2025.
- Aggregate sales proceeds target: up to $30.0 million.
- Commission rate for BofA: up to 3.0% of gross sales proceeds.
- Sales will be conducted via Nasdaq Global Select Market or other existing trading markets.
- The offering is pursuant to an effective S-3 shelf registration statement (No. 333-280597) declared effective on July 10, 2024.
FibroGen entered into a definitive agreement to sell its Chinese subsidiary, FibroGen International, to AstraZeneca for approximately $160 million. The transaction is expected to close by mid-2025 and will be used to repay an ~$80 million term loan facility with Morgan Stanley.
🚩 Red Flags
- Significant divestiture of core regional assets (China rights for roxadustat).
- Transaction subject to regulatory approval from China State Administration for Market Regulation.
- Estimated cash figures are preliminary/unaudited and subject to material adjustment.
📋 Key Facts
- Sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited.
- Total aggregate purchase price: approximately $160 million ($85M cash enterprise value + ~$75M estimated net cash in China).
- Transaction includes all rights to roxadustat in China, Hong Kong, and Macao (manufacturing, development, distribution, and commercialization).
- Proceeds intended to repay ~$80 million term loan facility with Morgan Stanley Tactical Value.
- Expected closing: Mid-2025, subject to China State Administration for Market Regulation approval.
- As of Dec 31, 2024, the company estimated $121.1 million in cash, cash equivalents, and accounts receivable.
FibroGen, Inc. announced the appointment of David DeLucia as Chief Financial Officer (CFO) effective December 16, 2024. Mr. DeLucia is an internal promotion, previously serving as VP of Financial Planning & Analysis and Investor Relations.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Appointment date: December 16, 2024
- New CFO: David DeLucia (previously VP, FP&A and Investor Relations at FibroGen)
- Mr. DeLucia is a CFA charterholder with ~15 years of life sciences financial leadership experience.
- Severance terms include 12 months base salary + 0.5x bonus for Change in Control (CIC) terminations, and 9 months base salary for Ordinary Course terminations.
FibroGen, Inc. issued an 8-K to announce its financial results for the third quarter ended September 30, 2024. The filing serves as a formal notice that a press release containing these results has been furnished.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2024
- Report date: November 12, 2024
- Filing includes Exhibit 99.1 (Press Release) regarding Q3 2024 financial results
- The information in Item 2.02 is furnished and not 'filed' for purposes of Section 18 of the Exchange Act.
FibroGen entered into a Lease Termination Agreement to accelerate the expiration of its San Francisco office lease to December 31, 2024. The company will pay a $10 million settlement to terminate its obligations for past rent and operating costs.
🚩 Red Flags
- Significant cash outflow ($10 million) to exit a real estate obligation.
- Part of 'continuing efforts... to reduce operating expenses and preserve cash,' indicating liquidity/burn rate concerns.
📋 Key Facts
- Entered into Lease Termination Agreement with ARE-San Francisco No.43 Owner, LLC on September 27, 2024.
- Lease expiration accelerated from original terms to December 31, 2024.
- Total settlement amount is $10 million, consisting of a one-time cash payment and a security deposit via letter of credit.
- The agreement covers past rent, operating costs, taxes, insurance, utilities, and lease modification payments.
FibroGen, Inc. received a notification from Nasdaq stating the company has been non-compliant with the minimum bid price requirement after its stock closed below $1.00 for 30 consecutive business days. The company has until March 11, 2025, to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq
- Potential requirement for a reverse stock split to regain compliance
- Persistent low share price (below $1.00) indicates significant market skepticism or capital erosion
📋 Key Facts
- Nasdaq notified FibroGen of a deficiency in the minimum closing bid price rule (Rule 5450(a)(1)).
- The stock closed below $1.00 for 30 consecutive business days prior to the notice.
- The company has a 180-day window to regain compliance, expiring March 11, 2025.
- To cure the deficiency, the stock must close at or above $1.00 for at least 10 consecutive business days.
- FibroGen may be eligible for an additional 180-day extension if it meets other listing standards and intends to effect a reverse stock split if necessary.
FibroGen, Inc. announced the resignation of three directors—Suzanne Blaug, Benjamin Cravatt, and Gerald Lema—effective September 30, 2024. The company has already appointed new committee members to fill the vacancies created by these departures.
🚩 Red Flags
- Simultaneous departure of three board members, including the former Chair of the Compensation Committee (Blaug) and a member of the Audit Committee (Lema).
📋 Key Facts
- Three directors (Suzanne Blaug, Benjamin Cravatt, and Gerald Lema) resigned effective September 30, 2024.
- The resignations are stated not to be the result of any disagreement with the Company or its management.
- New Audit Committee: Jeffrey L. Edwards (Chair), Dr. Maykin Ho, and James A. Schoeneck.
- New Compensation Committee: James A. Schoeneck (Chair) and Dr. Aoife Brennan.
- New Nominating and Corporate Governance Committee: James A. Schoeneck (Chair) and Jeffrey L. Edwards.
FibroGen, Inc. announced the termination of its Chief Financial Officer and Chief Medical Officer as part of a significant cost reduction plan initiated on August 2, 2024. Both executives will remain through transition periods ending in late 2024.
🚩 Red Flags
- Loss of key executive leadership (CFO and CMO) simultaneously.
- Departures are explicitly linked to a 'significant cost reduction plan,' indicating financial distress or restructuring.
- Succession planning for these critical roles is not detailed in the filing.
📋 Key Facts
- Termination of Juan Graham (CFO) effective December 15, 2024.
- Termination of Deyaa Adib, M.D. (CMO) effective November 1, 2024.
- Departures are part of a 'significant cost reduction plan' initiated on August 2, 2024.
- The company stated the departures are not due to disagreements with the company.
FibroGen, Inc. has initiated a major restructuring plan to reduce operating expenses following negative clinical trial data for pamrevlumab. The plan involves cutting approximately 75% of the U.S. workforce and incurring significant non-recurring charges.
🚩 Red Flags
- Significant workforce reduction (75% of U.S. staff) indicating severe operational contraction.
- Negative clinical trial data for a key asset (pamrevlumab) acting as the catalyst for restructuring.
- Substantial non-recurring cash charges ($16M-$18M) impacting near-term liquidity and earnings.
📋 Key Facts
- Initiated restructuring plan on August 2, 2024, due to negative pamrevlumab clinical trial data.
- Expected reduction of approximately 75% of the Company's U.S. workforce (127 employees noticed).
- Estimated non-recurring charges in the range of $16 million to $18 million.
- Charges primarily consist of severance, notice pay, accrued vacation, and payroll taxes.
- Implementation expected to be substantially complete by the end of Q1 2025.
FibroGen, Inc. issued an 8-K to announce its second quarter 2024 financial results and provide a business update for the period ended June 30, 2024.
📋 Key Facts
- Report date: August 6, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial results and business updates.
- Information under Item 2.02 is furnished, not filed, per SEC regulations.
FibroGen, Inc. held an investor presentation on June 26, 2024, featuring Dr. Rahul Aggarwal regarding the clinical development program for FG-3246 in treating prostate cancer.
📋 Key Facts
- Investor presentation titled 'Virtual KOL Investor Event Series Part II: Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Center' was delivered on June 26, 2024.
- The presentation featured Dr. Rahul Aggarwal from the University of California, San Francisco.
- Discussion focused on unmet needs and the evolving treatment landscape for prostate cancer.
FibroGen, Inc. reported the results of its 2024 annual meeting of stockholders held on June 5, 2024. The meeting included elections for the Board of Directors and approval of several key corporate matters including an equity incentive plan.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- The 2024 Annual Meeting of Stockholders was held on June 5, 2024.
- Class I nominees (Thane Wettig, James A. Schoeneck, and Maykin Ho, Ph.D.) were elected to the Board of Directors until the 2027 annual meeting.
- Stockholders approved the FibroGen, Inc. 2024 Equity Incentive Plan (Exhibit 10.1).
- Stockholders approved 'Say-on-Pay' advisory compensation for named executive officers.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
FibroGen, Inc. issued an 8-K to announce its financial results for the first quarter ended March 31, 2024.
📋 Key Facts
- Report date: May 6, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes a press release (Exhibit 99.1) regarding the quarterly financial results.
FibroGen, Inc. filed an 8-K to announce its financial results for the fourth quarter and full year ended December 31, 2023.
📋 Key Facts
- Report date: February 26, 2024
- Period covered: Quarter and Full Year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- Information under Item 2.02 is furnished but not 'filed' for liability purposes under Section 18 of the Exchange Act.